A Phase 1, Open-label, Two-part Study to Evaluate the Metabolism, Excretion, and Absolute Bioavailability of AG-221 in Healthy Adult Male Subjects

Trial Profile

A Phase 1, Open-label, Two-part Study to Evaluate the Metabolism, Excretion, and Absolute Bioavailability of AG-221 in Healthy Adult Male Subjects

Completed
Phase of Trial: Phase I

Latest Information Update: 14 Oct 2015

At a glance

  • Drugs Enasidenib (Primary)
  • Indications Haematological malignancies; Solid tumours
  • Focus Pharmacokinetics
  • Sponsors Celgene Corporation
  • Most Recent Events

    • 09 Oct 2015 Status changed from not yet recruiting to completed as reported by ClinicalTrials.gov.
    • 15 May 2015 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top